1-(4-氟-2-甲基苯基)哌嗪 | 307952-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(4-氟-2-甲基苯基)哌嗪
• 英文名称: 1-(4-Fluoro-2-methylphenyl)-piperazine
• 英文别名: 1-(4-Fluoro-2-methylphenyl)piperazine
• CAS: 307952-16-5
• 化学式: C₁₁H₁₅FN₂
• 分子量: 194.252
• InChiKey: QBLQGSYVHVJZKI-UHFFFAOYSA-N

物化性质

• 沸点：
  317.7±42.0 °C(Predicted)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-氟-2-甲基苯基)哌嗪 在 aluminium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 trans-1-[(2-phenylcyclopropyl)methyl]-4-(4-fluoro-2-methylphenyl)piperazine
  参考文献：
  名称：

  trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines:  Mixed Dopamine D₂/D₄ Receptor Antagonists as Potential Antipsychotic Agents

  摘要：

  The dopaminergic receptor profile of a series of trans-1-[(2-phenylcyclopropyl)methyl]-4-arylpiperazines was examined. Aromatic substitution patterns were varied with the goal of identifying a compound having affinities for the D-2 and D-4 receptors in a ratio similar to that observed for the atypical neuroleptic clozapine. The compounds (1S,2S)-trans-1-[(2-phenylcyclopropyl)methyl]-4-(2,4-dichlorophenyl)piperazine (5m) and (1S,2S)-trans-1-[(2-phenylcyclopropyl)methyl]-4-(2,4-dimethylphenyl)piperazine (5t) were selected for functional antagonists at D-2 and D-4 receptors and had a D-2/D-4 ratio approximating that of clozapine; they proved inactive in behavioral tests of antipsychotic activity.

  DOI：

  10.1021/jm990562x
• 作为产物：
  描述：

  4-氟-2-甲基苯胺 、 二(2-氯乙基)胺盐酸盐 以55%的产率得到1-(4-氟-2-甲基苯基)哌嗪
  参考文献：
  名称：

  Practical Method for Parallel Synthesis of Diversely Substituted 1- henylpiperazines

  摘要：

  已经开发出一种简单实用的方法，用于制备以替代1-苯基哌嗪构建块为内容的“库”，采用并行格式。

  DOI：

  10.2174/157017811799304386

文献信息

• Isoxazolecarboxamide derivatives
  申请人：Recordati, S.A., Chemical and Pharmacueticals Company

  公开号：US06365591B1

  公开（公告）日：2002-04-02

  The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

  该发明涉及新型N-(取代苯基)-N′-[ω-(3-取代苯基-4-异噁唑甲酰胺)烷基]哌嗪，它们的N-氧化物以及其药用可接受的盐。这些化合物具有增强的α1-肾上腺素受体选择性和降低血压活性较低。这些化合物在治疗下尿路梗阻综合征，包括良性前列腺增生（BPH），以及治疗下尿路症状（LUTS）和神经源性下尿路功能障碍（NLUTD）等疾病方面具有用途。
• Novel N-acylated heterocycles
  申请人：Recordati S.A.

  公开号：US20030162777A1

  公开（公告）日：2003-08-28

  Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.

  描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物，以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环，或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合，在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
• Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
  申请人：Gangloff Anthony R.

  公开号：US20100190763A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of the following formula: in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

  披露了以下公式的化合物： 其中R1、R2、R3、R4、R5、R6、R7、X和t在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，以及用于制备这些化合物的方法和中间体，以及使用这些化合物治疗与PARP活性相关的疾病、紊乱和状况的方法。
• [EN] HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS<br/>[FR] SULFONAMIDES D'HYDROXAMATE SERVANT D'INHIBITEURS D'ELIMINATION DU VIRUS CD23
  申请人：CELLTECH R&D LTD

  公开号：WO2004113312A1

  公开（公告）日：2004-12-29

  A class of piperazine and related heterocyclic derivatives, substituted at the 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.

  一类哌嗪和相关杂环衍生物，其在4位被取代芳基或杂环基取代，并在1位被乙磺酰基取代，乙磺酰基在2位被羟肟酸基取代，同时还被一系列替代基取代，这些化合物是CD23脱落的有效抑制剂，可用于治疗和/或预防过敏、炎症和肿瘤性疾病。
• Piperazine Derivatives of Dialkyl Oxindoles
  申请人：Volk Balazs

  公开号：US20070232619A1

  公开（公告）日：2007-10-04

  The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I), wherein R 1 stands for hydrogen, halogen, alkyl having 1-7 carbon atom(s) or sulfonamido; R 2 represents hydrogen or halogen; R 3 denotes hydrogen, alkyl having 1-7 carbon atom(s) optionally carrying an aryl substituent or aryl optionally carrying one or two halogen substituent(s); R 4 stands for alkyl having 1-7 carbon atom(s); R 5 represents a group of the general Formula (II a) or (II b), wherein Q and W each represents nitrogen or CH; R 6 , R 7 and R 8 each stands for hydrogen, halogen, trifluoromethyl, alkyl or alkoxy having 1-7 carbon atom(s), or R 6 and R 7 together represent ethylenedioxy; m is 0, 1, or 2; a is a single, double or triple bond; n is 0, 1 or 2; and pharmaceutically acceptable acid addition salts thereof which are useful in the treatment or prophylaxis of diseases of the central nervous system, the gastrointestinal system and the cardiovascular system.

  本发明涉及一般式（I）的新的3,3-二取代吲哚-2-酮衍生物，其中R1代表氢、卤素、具有1-7个碳原子的烷基或磺胺基；R2代表氢或卤素；R3代表氢、具有1-7个碳原子的烷基，可选地带有芳基取代基，或芳基，可选地带有一个或两个卤素取代基；R4代表具有1-7个碳原子的烷基；R5代表一般式（II a）或（II b）的基团，其中Q和W各自代表氮或CH；R6、R7和R8各自代表氢、卤素、三氟甲基、具有1-7个碳原子的烷基或烷氧基，或R6和R7一起代表乙二氧基；m为0、1或2；a为单键、双键或三键；n为0、1或2；以及其药学上可接受的酸盐，用于治疗或预防中枢神经系统、消化系统和心血管系统疾病。